Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
Actively Recruiting
Researchers are evaluating the impact of real-time audio-video telemedicine consultations with a neonatologist, called teleneonatology, on early health outcomes of at-risk newborns delivered in community hospitals. This study uses a stepped wedge cluster randomized design to compare early mortality, morbidity, and delivery room care between neonates receiving teleneonatology support and those receiving usual care. The trial is led by Mayo Clinic and focuses on newborns facing significant resuscitation needs shortly after birth. The study involves two groups one where at-risk neonates receive care from the community hospital team with telemedicine support from a neonatologist located at a regional neonatal intensive care unit, and a control group where neonates receive the hospitals usual care without telemedicine consultation. The telemedicine connection allows real-time, two-way audio and video communication during advanced neonatal resuscitations. The study includes neonates born preterm under 32 weeks or requiring advanced resuscitation interventions such as prolonged positive pressure ventilation, alternative airway placement, or chest compressions. Participants include clinicians attending newborn resuscitations and eligible neonates born at participating community hospitals. Researchers will monitor outcomes including mortality within 7 days, early neonatal morbidity, combined mortality and morbidity, and the highest level of resuscitation given in the delivery room within the first hour. The study tracks these outcomes to assess the effect of teleneonatology on newborn health during this critical early period. The total study duration extends through May 2029.
Actively Recruiting
Researchers are evaluating the effects of several drugsvismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclibin treating patients with progressive meningiomas, which are brain tumors that are growing, spreading, or worsening. This phase II trial specifically targets meningiomas with certain genetic mutations affecting pathways such as SMO, PTCH1, NF2, AKT1, PIK3CA, PTEN, and CDK. The study aims to measure how well these targeted drugs can slow tumor progression and improve response rates over six months. Participants are assigned to one of four treatment groups based on their tumors mutation profile. Those with SMO or PTCH1 mutations receive vismodegib once daily, NF2 mutations receive FAK inhibitor GSK2256098 twice daily, AKT1PIK3CAPTEN mutations receive capivasertib twice daily on days 1-4 weekly, and those with CDK pathway alterations receive abemaciclib every 12 hours. Treatment cycles last 28 days and continue unless the disease progresses or side effects become unacceptable. After completing treatment, participants are followed every six months for up to five years. During the study, participants undergo regular evaluations including imaging to measure tumor size and response, safety monitoring for adverse events, and assessments of progression-free and overall survival. Laboratory tests, electrocardiograms, and other clinical assessments support safety and eligibility monitoring. The main outcomes focus on progression-free survival at six months and confirmed tumor response, while secondary outcomes include overall survival and side effect rates. Participants remain under close observation throughout their treatment and follow-up periods.